MSB 3.42% $1.21 mesoblast limited

Ann: COVID ARDS Trial Topline 60-Day Results, page-1517

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 12,359 Posts.
    lightbulb Created with Sketch. 1105
    Hi Bedger,
    We must be on the cards for a EUA possibly a full approval.
    You can not ignore the reduction in mortality in the ARDS trial.

    Plus this is a global problem.

    Novartis would be throwing everything they have to persuade
    the FDA. The NIH who tipped in $50 mill would be keen on some
    approvals as well.

    Aloha.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.21
Change
0.040(3.42%)
Mkt cap ! $1.381B
Open High Low Value Volume
$1.17 $1.22 $1.17 $5.683M 4.776M

Buyers (Bids)

No. Vol. Price($)
1 20000 $1.21
 

Sellers (Offers)

Price($) Vol. No.
$1.21 19746 3
View Market Depth
Last trade - 16.10pm 01/10/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.